ELTP ELITE PHARMACEUTICALS INC /NV/
Pharmaceutical Preparations · OTC · SEC CIK 1053369 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.8%
TTM net income YoY333.0%
TTM EPS YoY50.0%
Revenue 3-yr CAGR52.2%
Net income 3-yr CAGR50.1%
Margins
Gross margin43.7%
Operating margin25.3%
Net margin41.6%
FCF margin6.0%
EBITDA margin26.1%
Returns
ROE65.6%
ROA46.1%
ROIC (approx.)52.7%
Asset turnover1.11x
Leverage & solvency
Liabilities / assets15.3%
Debt / equity0.00x
Current ratio6.65x
Interest coverage338.18x
Cash quality & payout
Operating cash flow / net income0.18x
Accruals ratio37.8%
Payout ratio—
Capex / revenue1.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 | FY20242024-03-31 | FY20232023-03-31 | FY20222022-03-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $148.87M | $84.04M | $56.63M | $34.16M | $32.26M |
| Cost of revenue | $73.85M | $43.96M | $30.27M | $17.56M | $17.47M |
| Gross profit | $75.02M | $40.09M | $26.36M | $16.59M | $14.80M |
| R&D expense | $5.74M | $7.96M | $6.88M | $6.20M | $4.05M |
| SG&A expense | $17.60M | $9.00M | $7.15M | $5.12M | $4.46M |
| Operating income | $49.11M | $19.60M | $10.79M | $3.68M | $5.07M |
| Interest expense | $111,361 | $128,234 | $137,438 | $1.11M | $191,816 |
| Pretax income | $56.81M | -$52,140 | $463,092 | $3.99M | $6.30M |
| Income tax | $11.94M | $4.26M | -$19.65M | $424,028 | -$1.74M |
| Net income | $44.87M | -$4.31M | $20.11M | $3.56M | $8.90M |
| EBITDA | $50.18M | $20.83M | $12.11M | $4.95M | $6.28M |
| EPS (basic) | 0.04 | 0.00 | 0.02 | 0.00 | 0.01 |
| EPS (diluted) | 0.03 | 0.00 | 0.02 | 0.00 | 0.01 |
| Weighted avg. shares (diluted) | 1.14B | 1.07B | 1.02B | 1.01B | 1.01B |
| Balance sheet | |||||
| Cash & equivalents | $29.80M | $11.77M | $7.54M | $7.83M | $8.54M |
| Receivables | $59.72M | $29.21M | $19.45M | $3.09M | $3.06M |
| Inventory | $21.26M | $16.24M | $12.93M | $9.55M | $6.74M |
| Current assets | $112.11M | $57.74M | $40.01M | $21.51M | $18.86M |
| PP&E, net | $10.18M | $10.33M | $10.18M | $10.43M | $5.95M |
| Intangibles | $4.79M | $5.64M | $6.34M | $6.34M | $6.63M |
| Total assets | $138.29M | $96.39M | $83.65M | $40.90M | $35.15M |
| Current liabilities | $17.39M | $11.84M | $13.05M | $7.83M | $6.69M |
| Long-term debt | — | — | — | — | $1.25M |
| Total debt | — | — | — | — | $1.25M |
| Total liabilities | $39.41M | $42.87M | $26.07M | $11.94M | $9.93M |
| Shareholders' equity | $98.88M | $53.52M | $57.58M | $28.96M | $25.22M |
| Net debt | — | — | — | — | -$7.29M |
| Shares outstanding | 1.08B | 1.07B | 1.07B | 1.01B | 1.01B |
| Cash flow statement | |||||
| Operating cash flow | $23.75M | $7.46M | -$3.24M | $3.34M | $6.51M |
| Capital expenditure | $925,626 | $1.63M | $809,653 | $5.74M | $498,566 |
| Free cash flow | $22.82M | $5.83M | -$4.04M | -$2.40M | $6.01M |
| Investing cash flow | -$925,626 | -$2.40M | -$809,653 | -$5.74M | -$498,566 |
| Financing cash flow | -$4.32M | -$825,740 | $3.34M | $1.70M | -$667,133 |
| Depreciation & amortization | $1.07M | $1.23M | $1.32M | $1.28M | $1.21M |
| Stock-based compensation | $176,507 | $227,565 | $159,921 | $39,325 | $14,353 |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.